Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robin Cornelissen

Showing results (41-50 of 58) with videos related to

Pageof 6
Sort By:
JTO Clinical and Research Reports|September 30, 2021
Ki67 (MIB-1) as a Prognostic Marker for Clinical Decision Making Before Extended Pleurectomy Decortication in Malignant Pleural MesotheliomaRobert A Belderbos, Alexander P W M Maat, Sara J Baart, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 23, 2023
Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4)Robin Cornelissen, Arsela Prelaj, Sophie Sun, et al.
Journal of Pain and Symptom Management|July 9, 2019
Is In-Hospital Mortality Higher in Patients With Metastatic Lung Cancer Who Received Treatment in the Last Month of Life? A Retrospective Cohort StudyAdinda Mieras, H Roeline W Pasman, Bregje D Onwuteaka-Philipsen, et al.
European Journal of Cancer Care|December 22, 2019
Chemotherapy and Tyrosine Kinase Inhibitors in the last month of life in patients with metastatic lung cancer: A patient file study in the NetherlandsAdinda Mieras, Annemarie Becker-Commissaris, H Roeline W Pasman, et al.
Journal for Immunotherapy of Cancer|April 3, 2020
T cell receptor repertoire characteristics both before and following immunotherapy correlate with clinical response in mesotheliomaHeleen Vroman, Giulia Balzaretti, Robert A Belderbos, et al.
The European Respiratory Journal|June 6, 2024
A randomised phase II study of extended pleurectomy/decortication preceded or followed by chemotherapy in patients with early-stage pleural mesothelioma: EORTC 1205Jo Raskin, Veerle Surmont, Alexander P W M Maat, et al.
Thorax|February 12, 2022
Incidence, treatment and survival of malignant pleural and peritoneal mesothelioma: a population-based studyJob P van Kooten, Robert A Belderbos, Jan H von der Thüsen, et al.
Lancet (London, England)|January 24, 2021
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trialPaul Baas, Arnaud Scherpereel, Anna K Nowak, et al.
Ebiomedicine|January 31, 2021
Immune monitoring in mesothelioma patients identifies novel immune-modulatory functions of gemcitabine associating with clinical responseFloris Dammeijer, Cornedine J De Gooijer, Mandy van Gulijk, et al.
Ebiomedicine|March 20, 2024
Hepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehensive clinical and pharmacokinetic analysisSophie M Ernst, Maaike M Hofman, Tessa E van der Horst, et al.
Pageof 6

Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
JTO Clinical and Research Reports|September 30, 2021
Ki67 (MIB-1) as a Prognostic Marker for Clinical Decision Making Before Extended Pleurectomy Decortication in Malignant Pleural MesotheliomaRobert A Belderbos, Alexander P W M Maat, Sara J Baart, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 23, 2023
Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4)Robin Cornelissen, Arsela Prelaj, Sophie Sun, et al.
Journal of Pain and Symptom Management|July 9, 2019
Is In-Hospital Mortality Higher in Patients With Metastatic Lung Cancer Who Received Treatment in the Last Month of Life? A Retrospective Cohort StudyAdinda Mieras, H Roeline W Pasman, Bregje D Onwuteaka-Philipsen, et al.
European Journal of Cancer Care|December 22, 2019
Chemotherapy and Tyrosine Kinase Inhibitors in the last month of life in patients with metastatic lung cancer: A patient file study in the NetherlandsAdinda Mieras, Annemarie Becker-Commissaris, H Roeline W Pasman, et al.
Journal for Immunotherapy of Cancer|April 3, 2020
T cell receptor repertoire characteristics both before and following immunotherapy correlate with clinical response in mesotheliomaHeleen Vroman, Giulia Balzaretti, Robert A Belderbos, et al.
The European Respiratory Journal|June 6, 2024
A randomised phase II study of extended pleurectomy/decortication preceded or followed by chemotherapy in patients with early-stage pleural mesothelioma: EORTC 1205Jo Raskin, Veerle Surmont, Alexander P W M Maat, et al.
Thorax|February 12, 2022
Incidence, treatment and survival of malignant pleural and peritoneal mesothelioma: a population-based studyJob P van Kooten, Robert A Belderbos, Jan H von der Thüsen, et al.
Lancet (London, England)|January 24, 2021
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trialPaul Baas, Arnaud Scherpereel, Anna K Nowak, et al.
Ebiomedicine|January 31, 2021
Immune monitoring in mesothelioma patients identifies novel immune-modulatory functions of gemcitabine associating with clinical responseFloris Dammeijer, Cornedine J De Gooijer, Mandy van Gulijk, et al.
Ebiomedicine|March 20, 2024
Hepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehensive clinical and pharmacokinetic analysisSophie M Ernst, Maaike M Hofman, Tessa E van der Horst, et al.
Pageof 6